nach oben

Open Access 08.12.2024 | Chest

Loss of pulmonary capillaries in idiopathic pulmonary arterial hypertension with low diffusion capacity is accompanied by early diffuse emphysema detected by ¹²⁹Xe MRI

verfasst von: Agilo Luitger Kern, Da-Hee Park, Jan Fuge, Jens M. Hohlfeld, Frank Wacker, Marius M. Hoeper, Karen M. Olsson, Jens Vogel-Claussen

Erschienen in: European Radiology

Abstract

Objectives

Recent studies suggest the existence of an idiopathic pulmonary arterial hypertension (IPAH) phenotype affecting mostly patients with a smoking history, characterised by low diffusion capacity for carbon monoxide (D_LCO) without clinically significant emphysema. This study’s objective was to test the hypothesis of a loss of pulmonary capillaries as an underlying mechanism by comparison to other patient groups with and without pulmonary hypertension (PH).

Materials and methods

Between March 2019 and June 2023, patients of four groups were recruited for this observational study: IPAH with preserved (1) and low D_LCO (2), combined pulmonary fibrosis and emphysema with PH (3), and emphysema without PH (4). Patients underwent clinical CT and ¹²⁹Xe MRI including dissolved-phase imaging yielding the ratio of ¹²⁹Xe in red blood cells and membrane tissues (RBC-M), chemical shift saturation recovery for determining RBC fraction η and diffusion-weighted imaging yielding surface-volume ratio. Kruskal–Wallis tests were used for statistical analysis.

Results

Twenty-nine participants were recruited, of which 22 (age 64 ± 10, 11 male, 5/5/7/5 for the individual groups) could be included in the analysis. RBC-M and η were reduced in IPAH with low versus preserved D_LCO and emphysema groups (p ≤ 0.01). CT low-attenuation area percentage was not increased in IPAH with low D_LCO compared to any group. ¹²⁹Xe MRI-derived surface-volume ratio was reduced in IPAH with low versus preserved D_LCO (p = 0.04).

Conclusion

Results are consistent with a loss of pulmonary capillaries in patients with IPAH and low D_LCO along with destruction of alveolar tissue, likely due to early diffuse emphysema.

Key Points

Question A loss of pulmonary capillaries has been suggested in patients with IPAH and low diffusion capacity without clinically significant emphysema on CT.

Findings ¹²⁹Xe uptake in red blood cells and lung surface-volume ratio were reduced in IPAH patients with low compared to preserved diffusion capacity.

Clinical relevance This study furthers the understanding of the underlying pathological mechanisms in IPAH with low diffusion capacity, providing evidence that loss of pulmonary capillaries is accompanied by alveolar tissue destruction despite near-normal CT.

ELECTRONIC SUPPLEMENTARY MATERIAL

Agilo Luitger Kern and Da-Hee Park contributed equally to this work.

Karen M. Olsson and Jens Vogel-Claussen jointly supervised to this work.

Supplementary information

The online version contains supplementary material available at https://doi.org/10.1007/s00330-024-11209-1.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

ADC

Apparent diffusion coefficient

COPD

Chronic obstructive pulmonary disease

CPFE

Combined pulmonary fibrosis and emphysema

CSSR

Chemical shift saturation recovery

D _LCO

Diffusion capacity of the lung for carbon monoxide

FEV₁

Forced expiratory volume in 1 s

IPAH

Idiopathic pulmonary arterial hypertension

Membrane tissues

Pulmonary hypertension

RBC

Red blood cell

Introduction

Idiopathic pulmonary arterial hypertension (IPAH) is a rare disease of the pulmonary vasculature characterised by pre-capillary pulmonary hypertension (PH) and can only be classified in the absence of other causes for PH [1]. Historically, IPAH predominantly affected young women. However, potentially due to changed demographics, IPAH is nowadays frequently diagnosed in elderly patients with cardiopulmonary comorbidities [2]. Among these, a distinct “lung phenotype” has emerged consisting of predominantly male patients with low diffusion capacity of the lung for carbon monoxide (D_LCO) and significant smoking history. Despite frequent hypoxaemia, lung function testing and CT show no or minimal signs of parenchymal lung disease [3, 4]. This phenotype is associated with high mortality and distinct from other diseases associated with pulmonary arterial hypertension and low D_LCO like pulmonary veno-occlusive disease, pulmonary capillary haemangiomatosis or systemic sclerosis.

Whereas smoking tobacco is not considered a risk factor for pulmonary arterial hypertension, long-standing tobacco exposure is hypothesised to cause direct damage to the alveolar-capillary membrane. Mice exposed to tobacco smoke showed endothelial cell apoptosis and loss of pulmonary capillaries [5]. Histopathology from 24 IPAH patients with a lung phenotype showed vascular pruning with capillary rarefication [6]. Direct damage to the alveolar-capillary membrane resulted in the loss of small pulmonary vessels and the term “vanishing pulmonary capillary syndrome” was proposed for this condition [7].

Smoking effects on the lungs were described in other diagnoses like chronic obstructive pulmonary disease (COPD) and combined pulmonary fibrosis and emphysema (CPFE) [8]. Recently, a vascular phenotype of COPD has been described [1]. There is typically only mild pulmonary arterial pressure elevation in COPD. Yet, a COPD subgroup with poor survival exists, characterised by moderate airflow limitation, severe precapillary PH, relatively low PaCO₂, strongly impaired D_LCO and progressive right heart failure [9]. CPFE displays a pattern of variable degrees of emphysema and fibrosis on CT. These patients seem to share clinical characteristics with IPAH with a lung phenotype [10].

Previous studies showed that even in patients with no or minimal changes in CT, histopathology may detect emphysematous and fibrotic changes [11]. However, as autopsies are rarely performed, verifying the existence of a vanishing pulmonary capillary syndrome histologically proved difficult.

Hyperpolarised gas MRI may assess lung microstructure and, e.g. emphysematous changes through increases in apparent diffusion coefficient (ADC) [12] noninvasively. Since xenon is taken up in lung tissue and blood and ¹²⁹Xe experiences strong chemical shifts, ¹²⁹Xe MRI is sensitive to alveolar-capillary diffusion and microvascular pulmonary blood volume [13]. With the appropriate choice of sequence parameters, ¹²⁹Xe MRI metrics are specific to the gas uptake region and pulmonary capillaries as opposed to, e.g. dynamic contrast-enhanced MRI. Imaging of the ¹²⁹Xe dissolved phase and dynamic acquisition of cardiogenic oscillations of ¹²⁹Xe in red blood cells (RBC) may differentiate cardiopulmonary diseases and may provide information on pre- or postcapillary involvement in PH [14]. Although widespread clinical application is hampered by limited dissemination of necessary equipment, hyperpolarised ¹²⁹Xe MRI is a useful tool for clinical research and the field of ¹²⁹Xe MRI continues to grow.

We hypothesise that patients with IPAH and low D_LCO differ from other patient groups by a loss of pulmonary capillaries, as judged by the ratio of ¹²⁹Xe in RBCs and membrane tissues (M). The purpose of this study was to test this hypothesis and to evaluate alveolar microstructure by comparing results from ¹²⁹Xe MRI in IPAH with low D_LCO with those from IPAH with preserved D_LCO, as well as with those from PH patients with CPFE and with those from patients with emphysema without echocardiographic signs of PH.

Materials and methods

Ethical approval for this observational, prospective study was granted by the institutional review board of Hannover Medical School. MRI was performed at Hannover Medical School between 03/2019 and 06/2023. Participants gave written informed consent.

Participants

Four patient groups were consecutively recruited from the outpatient clinic of the Department of Respiratory Medicine and Infectious Diseases of Hannover Medical School:

Patients with IPAH and preserved D_LCO (≥ 45% of predicted, based on findings in [4]) and forced expiratory volume in 1 s (FEV₁) of ≥ 60% predicted;

Patients with IPAH and low D_LCO (< 45% predicted) and FEV₁ ≥ 60% predicted without clinically significant parenchymal lung disease on CT;

Patients with CPFE on chest CT and PH;

Patients with emphysema without PH diagnosis.

Lung function testing, blood gas analyses, right-heart catheterisation (groups 1–3), as well as echocardiography (group 4) were part of clinical assessments. Right heart catheterisation was done at the time of PH diagnosis (except for patients with emphysema in whom echocardiography did not show signs of PH). PH was defined as mean pulmonary arterial pressure > 20 mmHg [1]. Clinical chest CT was available within 12 months. Exclusion criteria were pregnancy and MRI contraindications.

¹²⁹Xe application

Locally produced hyperpolarised ¹²⁹Xe (isotopically enriched ¹²⁹Xe, polarisation 20–30%, Model 9810, Polarean) was authorised as a medical device for research applications. Doses were topped up with nitrogen to 1 L and dispensed into Tedlar bags (Jensen Inert Products). Subjects were instructed to exhale forcefully and inhale the dose in one breath. For the first two doses, in participants with vital capacity > 3 L, a second Tedlar bag containing air was connected to achieve a volume of 1/3 vital capacity [15]. For the last dose, participants were coached to further inhale room air after ¹²⁹Xe to reach full lung inflation which may be beneficial for the repeatability of chemical shift saturation recovery (CSSR) measurements [16]. MRI was performed in breathhold. Vital signs were monitored by a physician during ¹²⁹Xe applications.

Imaging

¹²⁹Xe MRI was performed at 1.5 T/17.6 MHz (Avanto, Siemens) using a linearly-polarised birdcage coil with a 16-channel receive array (Rapid Biomedical) and self-developed pulse sequences. Common sequence parameters are summarised in Table 1.

Table 1

Sequence parameters

Sequence	TR/ms	TE/ms	Flip angle/°	Reconstructed FOV/mm	Reconstructed matrix
Ventilation imaging	3.2	1.6	~10	384 × 384 × 384	96 × 96 × 96
Dissolved-phase imaging	18	Echo train 1: 0.61/2.23/3.85 Echo train 2: 1.42/3.04	21 (dissolved)/0.4 (gas)	320 × 320 × 320	48 × 48 × 48
Fixed-TR dynamic spectroscopy	36	1.2	60	n/a	n/a
CSSR	Variable	0.7	~27 (excitation using maximum RF power)	n/a	n/a
Diffusion-weighted imaging	57	41.6	7.4	400 × 400 × 240	64 × 64 × 6

The sequence parameters for dissolved-phase imaging are comparable to those previously established for multi-echo techniques and to ¹²⁹Xe clinical trial consortium recommendations for multi-site trials [15, 28]. Compared to the recommendations, ventilation imaging uses a radial trajectory facilitating acceleration. Diffusion-weighted imaging uses shorter diffusion times to facilitate the estimation of surface-volume ratio. The impact of frequency-selective excitation in fixed-TR dynamic spectroscopy on dissolved-phase ratios is assessed in the supplemental material

The first dose was used for ventilation imaging using a 3D radial balanced steady-state free precession sequence and transmitter calibration. A second dose (600–800 mL ¹²⁹Xe, dose equivalent to ~130 mL) was used for fixed-TR dynamic dissolved-phase spectroscopy and dissolved-phase imaging. A third dose (500–600 mL ¹²⁹Xe) was used for diffusion-weighted imaging and CSSR with a combined imaging time of 11 s [17].

Dissolved-phase imaging [17] was performed using five echoes in the dissolved phase. Ratio maps M-gas, RBC-gas, and RBC-M were formed and whole-lung averages were calculated within an automatically generated mask based on gas-phase SNR. Whole-lung RBC-M was defined as the primary dependent variable.

Fixed-TR dynamic spectroscopy was not spatially selective and employed excitation at 222.5 ppm using a 2.2 ms frequency-selective radiofrequency pulse systematically increasing RBC signals. Sequence parameters included 512 points, a bandwidth of 16.7 kHz, and 160 measurements. Two Lorentzians including a phase term were fitted to real parts of spectra after zeroth order phasing corresponding to M and RBC. The median RBC-M chemical shift difference was determined. The function

$$f\left(n\right)=m\left(1+a\,{\mathrm{sin}}\left(r\,n+\varphi \right)\right)+d\left(n-\frac{{N}_{{{\rm{meas}}}}}{2}\right)$$

(1)

was fitted to the ratio of magnitudes to quantify the average RBC-M ratio (m) and oscillation amplitude (a). N_meas denotes the number of measurements (discarding the first 10%), n is the excitation number, r is proportional to heart rate, φ a phase factor and d accounts for signal drifts.

In CSSR spectroscopy, two 2.4 ms rectangular radiofrequency pulses saturated the dissolved-phase magnetisation. Dissolved-phase signal-buildup/gas uptake at delay times of 3–600 ms was probed using a 1.2 ms Gaussian pulse without localisation and free-induction decays sampled with bandwidth 16.7 kHz. ¹²⁹Xe in the three compartments was quantified after zeroth- and first-order phasing by numerical integration of real parts. CSSR data were analysed by fitting a generalised model of ¹²⁹Xe septal uptake [18] yielding membrane permeability κ defined as the ratio of diffusion coefficient and membrane thickness, describing delayed uptake to RBCs, RBC fraction η derived from relative RBC signal intensity at the time of saturation of alveolar septa with ¹²⁹Xe, as well as capillary transit time τ derived from RBC signal increase at high delay times.

From diffusion-weighted ¹²⁹Xe MRI, whole-lung time-dependent ADCs were calculated and the whole-lung ratio of alveolar surface to gas volume quantified from data with 920 µs, 1140 µs, 1400 µs, 1660 µs, and 1960 µs diffusion time with 11, 9, 8, 7, and 7 repetitions of the diffusion-sensitising gradients at a constant b-value of 3 s/cm². A second-order approximation of ADC time dependence was assumed [19].

Chest CT was evaluated by a radiologist (J.V.C., 21 years of experience). Lungs were segmented and low-attenuation area percentage (voxels with attenuation ≤ −950 HU) was quantified automatically using Aview (version 1.1.42.53, Coreline Soft).

Statistical analysis

Statistical analysis was performed by AK using subroutines in R (version 4.1.2). Kruskal–Wallis tests were performed to assess differences between groups. Post-hoc analysis was performed using Dunn tests including Holm p-value adjustment (kwManyOneDunnTest, package PMCMRplus, version 1.9.10) to test pairwise differences between IPAH with low D_LCO and all other groups. Correlations were assessed using Pearson’s correlation. The significance level was 0.05 two-sided. Results are presented as median (interquartile range).

Results

Participants

Out of the 29 initially recruited participants 7 were excluded resulting in 22 participants for analysis: 5 participants with IPAH and preserved D_LCO, 5 participants with IPAH and low D_LCO, 7 PH participants with CPFE and 5 participants with pulmonary emphysema without PH. Results for exclusion were notable emphysema or parenchymal lung disease on chest CT in patients of the IPAH low D_LCO group (four cases) or suspected pulmonary veno-occlusive disease based on their clinical phenotype (two cases) or histological results (one case). Data from diffusion-weighted imaging and CSSR could not be evaluated in one CPFE patient due to inadequate SNR.

Table 2 summarises participant demographics and clinical characteristics. The median interval between right heart catheterisation and MRI was 1.1 years. Participants with IPAH and preserved D_LCO were comparatively young (median 55 years), the majority never smoked. FEV₁ and D_LCO were preserved with near-normal PaO₂ and low PaCO₂. Right-heart catheterisation at PH diagnosis showed severe pre-capillary PH. Patients received double (four cases) or triple (one case) combination therapy for PH. Four patients received macitentan, three received a PDE5 inhibitor, two riociguat, one selexipag, and one imatinib.

Table 2

Participant demographics and clinical characteristics

	All patients	IPAH preserved D_LCO	IPAH low D_LCO (lung phenotype)	CPFE	Emphysema
Number	22	5	5	7	5
Age at study, years	65 (57–71)	55 (43–59)	65 (61–72)	71 (63–79)	66 (62–70)
Sex, male, %	50	60	40	71	20
D_LCO, % pred.	33 (28–40)	72 (66–82)	29 (27–31)	33 (24–38)	29 (19–36)
FEV₁, % pred.	73 (63–94)	94 (87–94)	74 (71–92)	81 (66–94)	39 (23–47)
FVC, % pred.	94 (79–104)	89 (88–110)	98 (93–102)	80 (79–103)	71 (70–102)
TLC, % pred.	100 (84–107)	89 (83–102)	100 (93–105)	86 (67–103)	113 (106–127)
RV, % pred.	106 (85–137)	86 (85–98)	121 (88–131)	96 (61–132)	173 (156–213)
Body mass index, kg/m²	26 (24–29)	25 (21–28)	27 (26–34)	27 (25–29)	22 (21–26)
World Health Organization functional class
I, n (%)	2 (12)	2 (40)	0 (0)	0 (0)	/
II, n (%)	4 (24)	2 (40)	1 (20)	1 (14)	/
III, n (%)	10 (59)	1 (20)	3 (60)	6 (86)	/
IV, n (%)	1 (6)	0 (0)	1 (20)	0 (0)	/
6-min walk distance, m	346 (251–387)	558 (484–546)	252 (177–335)	353 (250–373)	/
N-terminal pro-B-type natriuretic peptide, ng/L	279 (69–1576)	60 (40–141)	306 (132–2675)	1212 (643–2786)	/
Haemoglobin, g/dL	15.5 (14.3–16.9)	15.4 (14.4–17.0)	15.8 (13.6–16.7)	15.2 (14.5–16.5)	15.6 (14.9–17.4)
Arterial partial pressure of oxygen, mmHg	61 (54–72)	77 (65–79)	57 (54–62)	58 (53–62)	60 (55–68)
Partial pressure of carbon dioxide, mmHg	36 (34–39)	34 (33–39)	35 (32–40)	34 (33–36)	39 (35–42)
Oxygen saturation, %	92 (90–95)	96 (95–97)	91 (88–93)	91 (88–92)	92 (92–95)
Oxygen supplementation, n (%)	13 (59)	0 (0)	4 (80)	5 (71)	4 (80)
Smoking status, n (%)
Active	3 (14)	0 (0)	1 (20)	2 (29)	0 (0)
Former	15 (68)	2 (40)	3 (60)	5 (71)	5 (100)
Never	4 (18)	3 (60)	1 (20)	0 (0)	0 (0)
Pack years	42 (5–50)	0 (0–3)	30 (23–44)	50 (45–65)	40 (13–49)
Haemodynamics
Right atrial pressure, mmHg	10 (7–12)	8 (5–9)	10 (7–12)	12 (8–13)	/
Mean pulmonary arterial pressure, mmHg	47 (40–54)	53 (42–59)	44 (43–48)	47 (36–54)	/
Pulmonary arterial wedge pressure, mmHg	11 (8–14)	9 (8–11)	14 (10–15)	11 (6–15)	/
Cardiac index, L/min/m²	2.2 (2.0–2.4)	1.8 (1.6–1.9)	2.3 (2.2–2.6)	2.2 (2.0–2.4)	/
Pulmonary vascular resistance, Wood units	8 (6–13)	14 (8–16)	7 (7–8)	9 (5–11)	/
Mixed venous oxygen saturation, %	63 (57–67)	67 (56–68)	60 (58–66)	54 (42–66)	/

Values describing a distribution are shown as median (interquartile range)

CPFE combined pulmonary fibrosis and emphysema, D_LCO diffusion capacity of the lung for carbon monoxide, FEV₁ forced expiratory volume in 1 s, FVC forced vital capacity, IPAH idiopathic pulmonary arterial hypertension, RV residual volume, TLC total lung capacity

Patients with IPAH and low D_LCO were comparatively older (median 65 years) and had a substantial smoking history (median 30 pack-years). FEV₁ was mildly reduced, D_LCO was severely reduced, and these participants were more hypoxaemic. These participants also had severe PH comparable to participants with IPAH and preserved D_LCO. All patients were treated with a PDE5 inhibitor, two also received macitentan.

Patients with CPFE and PH were similar in age to patients with IPAH and low D_LCO and predominantly male. Patients with CPFE and PH also had a substantial smoking history (median 50 pack-years). D_LCO was similar to patients with IPAH and low D_LCO. All patients were treated with a PDE5 inhibitor, one additionally with macitentan and selexipag.

Patients with emphysema without PH diagnosis, similar in age to patients with IPAH and low D_LCO, had markedly reduced FEV₁ and presented with comparable, very low D_LCO (median 29% pred.). Echocardiography showed no signs of PH in these patients.

Imaging

Representative CT images for participants of all groups are depicted in Figs. 1a–4a, respectively. Low-attenuation area percentages are shown in Fig. 5a. Values were significantly different between groups (p = 0.02) but not increased in the IPAH with low D_LCO group compared to other groups.

Lung surface-volume ratio from time-dependent diffusion measurements was significantly different between groups (p < 0.001), see Fig. 5b. In contrast to low-attenuation area percentage, the surface-volume ratio was significantly reduced in participants of the IPAH with low D_LCO group compared to the IPAH with preserved D_LCO group (p = 0.04). The median surface-volume ratio was lowest in the emphysema group.

Representative ratio maps of ¹²⁹Xe in RBC and M from dissolved-phase imaging are shown in Figs. 1b–4b. The RBC-M ratio was diffusely low throughout the lung parenchyma in the IPAH with low D_LCO group (Fig. 2b). Whole-lung averages were significantly different between groups (p = 0.001), Fig. 6a. In post-hoc analysis, RBC-M was significantly reduced in the IPAH with low D_LCO group compared to both the IPAH with preserved D_LCO group (p = 0.006) and the emphysema group (p = 0.006). No significant difference was observed in comparison to the CPFE group (p = 0.45).

The RBC fraction η from CSSR was significantly different between the groups (p = 0.001), Fig. 6e. η was significantly reduced in the IPAH with low D_LCO group compared to the IPAH with preserved D_LCO group (p = 0.004) and to the emphysema group (p = 0.004). No difference was observed with respect to the CPFE group (p = 0.33). The parameters κ and τ were not significantly different between the four groups (p = 0.36 and 0.05). Interestingly, capillary transit time τ tended to be lower in the IPAH with low D_LCO (0.24 s (0.20–0.50 s)) than in the IPAH with preserved D_LCO group (0.91 s (0.66–1.12 s)), Fig. 6f.

Results from fixed-TR dynamic spectroscopy of the ¹²⁹Xe dissolved phase are summarised in supporting Fig. 1. Average RBC-M was different between groups (p = 0.002) and reduced in IPAH with low D_LCO compared to IPAH with preserved D_LCO (p = 0.02) and the emphysema group (p = 0.03). Oscillation amplitudes were significantly different between groups (p = 0.02) but post-hoc analysis showed no significant differences. Both IPAH groups tended to have low oscillation amplitudes. The RBC-M chemical shift difference was significantly different between groups (p = 0.002) and reduced in the IPAH with low D_LCO group compared to the IPAH with preserved D_LCO group (p = 0.005).

Ventilation defect percentage was significantly different between groups (p = 0.02) and highest in the emphysema group, but not different between IPAH with low D_LCO compared to IPAH with preserved D_LCO (p = 0.67).

Correlations

Cardiac index from right-heart catheterisation and capillary transit time τ were inversely correlated in the first three groups (R = −0.64, p = 0.008). There was a moderate correlation between CT-derived low-attenuation area and surface-volume ratio from ¹²⁹Xe MRI (R = −0.45, p = 0.04). RBC-M chemical shift difference was correlated with oxygen partial pressure from blood gas analysis (R = 0.55, p = 0.006). RBC-M from fixed-TR dynamic spectroscopy was strongly correlated with whole-lung averages of imaging (R = 0.98, p < 0.001), supporting Fig. 2, and with η (R = 0.81, p < 0.001), but not with κ (R = −0.17, p = 0.45). Surface-volume ratio from diffusion-weighted imaging was strongly correlated with whole-lung M-Gas from dissolved-phase imaging (R = 0.82, p < 0.001) but not RBC-M (R = −0.18, p = 0.44).

Discussion

This study was performed to non-invasively detect a potential loss of pulmonary capillaries in patients with IPAH and low D_LCO, as well as to evaluate lung microstructure. We found a significantly reduced RBC-M ratio, as well as RBC fraction η in the IPAH with a low D_LCO group compared to both the preserved D_LCO group and emphysema groups. At the same time, the lung surface-volume ratio derived from ¹²⁹Xe ADCs in lung airspaces was significantly decreased in IPAH with low D_LCO compared to IPAH with preserved D_LCO although CT did not show signs of clinically significant macroscopic emphysema in IPAH with low D_LCO.

These findings support the hypothesis of a loss of pulmonary capillaries in participants of the IPAH with low D_LCO group, as seen by the significant reduction in RBC-M and the RBC fraction η. Furthermore, results from ¹²⁹Xe MRI also suggest early emphysematous changes in IPAH with low D_LCO as seen by the reduced lung surface-volume ratio despite negligible low-attenuation area on CT. This indicates that alveolar tissue destruction as part of early diffuse emphysema is likely contributing to D_LCO reduction in IPAH with low D_LCO. Four of five participants with IPAH and low D_LCO were former or active smokers. One participant never smoked but was a metalworker with occupational exposure to toxic fumes for several decades.

Our findings suggest that the IPAH with low D_LCO group mainly reflects the vascular phenotype of COPD, corresponding to World Health Organization PH group 3, with predominantly pulmonary capillary loss or dysfunction with relatively mild FEV₁ reduction and diffuse alveolar tissue destruction as part of early emphysema leading to severe alveolar membrane dysfunction with severely reduced D_LCO and resulting hypoxia. Measured pathophysiological changes are summarised in Table 3 with reference values from healthy subjects [17].

Table 3

Summary of pathophysiological changes

Quantity	IPAH preserved D_LCO	IPAH low D_LCO (lung phenotype)	CPFE	Emphysema
Airspace enlargement
LAA (CT)	0	0	+	++
S/V (¹²⁹Xe MRI)	0	−	(−)	−−
Capillary rarefication
RBC fraction η	0	−	−	0
RBC-TP	0	−	−	0
Capillary blood flow
Capillary transit time τ	+	−	0	0
RBC oscillation amplitude	−	−	0	0
Alveolar membrane function
Membrane permeability κ	−	−	−	−
RBC chemical shift (oxygenation)	0	−−	−−	−
Ventilation heterogeneity
Ventilation defect percentage	+	+	+	++
FEV₁ as % of predicted value	0	−	−	−−

Reference values for parameters from CSSR measurements in a group of 12 healthy volunteers reported in [17] (7 male/5 female, age 49 years ± 14 years) are κ: 0.051 cm/s ± 0.023 cm/s, η: 0.247 ± 0.041, τ: 0.67 s ± 0.18 s. Similarly, for fixed-TR dynamic spectroscopy, reference values are average RBC-M: 1.04 ± 0.17, RBC oscillation amplitude: 3.5% ± 0.5%, RBC chemical shift 18.7 ppm ± 0.4 ppm

++ strongly increased, + increased, 0 equal, − reduced, −− strongly reduced, CPFE combined pulmonary fibrosis and emphysema, D_LCO diffusion capacity of the lung for carbon monoxide, FEV₁ forced expiratory volume in 1 s, GP gas phase, IPAH idiopathic pulmonary arterial hypertension, LAA low-attenuation area, M membrane tissues, RBC red blood cell, S/V surface/volume

The different findings from CT and MRI may suggest an increased sensitivity of ¹²⁹Xe diffusion-weighted MRI for early emphysema detection. Recent work showed the potential of ¹²⁹Xe diffusion-weighted imaging to detect airspace enlargement in normal-appearing areas of the fibrotic lung [20]. ¹²⁹Xe diffusion-weighted imaging and assessment of RBC signal may add value to patient phenotyping.

Results from fixed-TR dynamic spectroscopy of the dissolved phase are consistent with those from dissolved-phase imaging despite the systematic difference in RBC-M owing to frequency-selective excitation and an offset in the scatter plot (supporting Fig. 2), possibly due to T₂* differences or non-Lorentzian line-shapes. The fact that RBC-M strongly correlates with η but not κ suggests that RBC-M in these patients is relatively unaffected by membrane permeability and mostly reflective of capillary density within alveolar tissue. The relative RBC signal from dissolved-phase imaging has been suggested to be reflective of capillary volume in analogy to the Roughton–Forster model [21].

Post-hoc analysis of RBC oscillation amplitudes showed no significant differences likely due to limited sample size. There was a trend towards reduced oscillation amplitudes in precapillary PAH compared to patients with emphysema without PH. The reduced RBC-M chemical shift difference in patients with IPAH and low D_LCO is likely due to reduced oxygenation [22]. Furthermore, we observed a tendency for higher capillary flow in the IPAH with low D_LCO group compared to the IPAH group with preserved D_LCO. This is consistent with the hypothesis of capillary loss leading to increased capillary flow in remaining capillaries, shortening the oxygenation time. However, the influence of cardiac index on capillary transit time should be considered given that data from right-heart catheterisation showed a higher cardiac index in the IPAH with a low D_LCO group on average. Interestingly, both capillary transit time and the product of RBC fraction η and surface-volume ratio were lower in IPAH with low D_LCO compared to emphysema patients without PH, possibly reflecting a larger loss of capillary surface area.

Limitations

Measures of ¹²⁹Xe gas uptake, particularly RBC-M, depending on age and sex in healthy subjects with increased values in males and younger age [23]. In addition, dissolved-phase ratios depend on haemoglobin [24] and could potentially also depend on oxygenation [25]. Future work should concentrate on the further establishment of reference values, as well as on the exact influence of confounding variables. Correlations between invasive haemodynamics and MRI findings must be interpreted with caution as these measurements were not obtained simultaneously and PAH treatments were initiated in between, potentially affecting pulmonary blood flow.

The parameters from the generalised CSSR model in [18] have not been validated by comparison to gold standard measurements. This study showed a correlation of capillary transit time with cardiac index. Results for κ may be affected by noise and uncertainties in transmitter calibration.

The inability of some participants to hold their breath long enough may have influenced the results. In particular, imprecision and bias may arise from the dependence of dissolved-phase ratios on lung inflation [26]. This was partly addressed by administering gas volumes normalised to spirometry. Previous studies suggest an influence of lung size which possibly cannot be addressed by standardised breathing manoeuvres [27].

The generalizability of the results of this single-centre study to other centres with different patient cohorts and imaging methods is an open question. Multi-centre studies with larger sample sizes are needed but are hampered by limited dissemination of ¹²⁹Xe MRI.

Conclusion

Our results are consistent with a loss of pulmonary capillaries in patients with IPAH and low D_LCO in conjunction with the destruction of alveolar membranes, likely due to early diffuse emphysema.

Supplementary information

The online version contains supplementary material available at https://doi.org/10.1007/s00330-024-11209-1.

Acknowledgements

This work was funded by the German Center for Lung Research (DZL).

Compliance with ethical standards

Guarantor

The scientific guarantor of this publication is Jens Vogel-Claussen.

Conflict of interest

The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.

Statistics and biometry

No complex statistical methods were necessary for this paper.

Written informed consent was obtained from all subjects (patients) in this study.

Ethical approval

Institutional Review Board approval was obtained.

Study subjects or cohorts overlap

None.

Methodology

Prospective
Cross-sectional study
Performed at one institution

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Jetzt testen ¹

e.Med Radiologie

Kombi-Abonnement

Mit e.Med Radiologie erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Radiologie, den Premium-Inhalten der radiologischen Fachzeitschriften, inklusive einer gedruckten Radiologie-Zeitschrift Ihrer Wahl.

Jetzt testen ²

Supplementary information

ELECTRONIC SUPPLEMENTARY MATERIAL

Humbert M, Kovacs G, Hoeper MM et al (2022) 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 43:3618–3731. https://doi.org/10.1093/eurheartj/ehac237CrossRefPubMed

Hoeper MM, Pausch C, Grünig E et al (2020) Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry. J Hear Lung Transplant 39:1435–1444. https://doi.org/10.1016/j.healun.2020.09.011CrossRef

Olsson KM, Fuge J, Meyer K, Welte T, Hoeper MM (2017) More on idiopathic pulmonary arterial hypertension with a low diffusing capacity. Eur Respir J 50:1700354. https://doi.org/10.1183/13993003.00354-2017CrossRefPubMed

Trip P, Nossent EJ, de Man FS et al (2013) Severely reduced diffusion capacity in idiopathic pulmonary arterial hypertension: patient characteristics and treatment responses. Eur Respir J 42:1575–1585. https://doi.org/10.1183/09031936.00184412CrossRefPubMed

Seimetz M, Parajuli N, Pichl A et al (2011) Inducible NOS inhibition reverses tobacco-smoke-induced emphysema and pulmonary hypertension in mice. Cell 147:293–305. https://doi.org/10.1016/j.cell.2011.08.035CrossRefPubMed

Nossent EJ, Smits J, Seegers C et al (2022) A new clinical phenotype with non-plexiform vasculopathy and distinctive microvessel remodeling among idiopathic pulmonary arterial hypertension patients. In: D96 EMBARCADERO: MACHINES AND DEEP PHENOTYPING OF THE PULMONARY CIRCULATION. American Thoracic Society, pp A5302–A5302. https://doi.org/10.1164/ajrccm-conference.2022.205.1_MeetingAbstracts.A5302

Hoeper MM, Vonk-Noordegraaf A (2017) Is there a vanishing pulmonary capillary syndrome? Lancet Respir Med 5:676–678. https://doi.org/10.1016/S2213-2600(17)30291-6CrossRefPubMed

Christenson SA, Smith BM, Bafadhel M, Putcha N (2022) Chronic obstructive pulmonary disease. Lancet 399:2227–2242. https://doi.org/10.1016/S0140-6736(22)00470-6CrossRefPubMed

Kovacs G, Agusti A, Barberà JA et al (2018) Pulmonary vascular involvement in chronic obstructive pulmonary disease. Is there a pulmonary vascular phenotype? Am J Respir Crit Care Med 198:1000–1011. https://doi.org/10.1164/rccm.201801-0095PPCrossRefPubMed

10.

Hoeper MM, Dwivedi K, Pausch C et al (2022) Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis. Lancet Respir Med 10:937–948. https://doi.org/10.1016/S2213-2600(22)00097-2CrossRefPubMedPubMedCentral

11.

El-Kersh K, Perez RL, Smith JS, Fraig M (2013) Smoking-related interstitial fibrosis (SRIF) and pulmonary hypertension. Case Rep 2013:bcr2013008970. https://doi.org/10.1136/bcr-2013-008970CrossRef

12.

Tafti S, Garrison WJ, Mugler JP et al (2020) Emphysema index based on hyperpolarised 3 He or 129 Xe diffusion MRI: performance and comparison with quantitative CT and pulmonary function tests. Radiology 297:201–210. https://doi.org/10.1148/radiol.2020192804CrossRefPubMed

13.

Kern AL, Vogel-Claussen J (2018) Hyperpolarized gas MRI in pulmonology. Br J Radiol 91:20170647. https://doi.org/10.1259/bjr.20170647CrossRefPubMedPubMedCentral

14.

Wang Z, Bier EA, Swaminathan A et al (2019) Diverse cardiopulmonary diseases are associated with distinct xenon magnetic resonance imaging signatures. Eur Respir J 54:1900831. https://doi.org/10.1183/13993003.00831-2019CrossRefPubMedPubMedCentral

15.

Qing K, Ruppert K, Jiang Y et al (2014) Regional mapping of gas uptake by blood and tissue in the human lung using hyperpolarized xenon-129 MRI. J Magn Reson Imaging 39:346–359. https://doi.org/10.1002/jmri.24181CrossRefPubMed

16.

Stewart NJ, Horn FC, Norquay G et al (2017) Reproducibility of quantitative indices of lung function and microstructure from ¹²⁹Xe chemical shift saturation recovery (CSSR) MR spectroscopy. Magn Reson Med 77:2107–2113. https://doi.org/10.1002/mrm.26310CrossRefPubMed

17.

Kern AL, Pink I, Bonifacius A et al (2024) Alveolar membrane and capillary function in COVID-19 convalescents: insights from chest MRI. Eur Radiol. https://doi.org/10.1007/s00330-024-10669-9

18.

Kern A, Olsson K, Kaireit T et al (2020) Assessment of interstitial membrane permeability using a generalized model of 129Xe septal uptake in the lung. In: Proceedings of the International Society for Magnetic Resonance in Medicine. ISMRM, pp 2371

19.

Kern AL, Gutberlet M, Moher Alsady T et al (2020) Investigating short-time diffusion of hyperpolarized 129 Xe in lung air spaces and tissue: a feasibility study in chronic obstructive pulmonary disease patients. Magn Reson Med 84:2133–2146. https://doi.org/10.1002/mrm.28264CrossRefPubMed

20.

Chan H-F, Weatherley ND, Biancardi AM et al (2023) Voxel-wise comparison of Co-registered quantitative CT and hyperpolarised gas diffusion-weighted MRI measurements in IPF. Diagnostics 13:3497. https://doi.org/10.3390/diagnostics13233497CrossRefPubMedPubMedCentral

21.

Wang Z, Rankine L, Bier EA et al (2021) Using hyperpolarized 129 Xe gas-exchange MRI to model the regional airspace, membrane, and capillary contributions to diffusing capacity. J Appl Physiol (1985) 130:1398–1409. https://doi.org/10.1152/japplphysiol.00702.2020CrossRefPubMedPubMedCentral

22.

Wolber J, Cherubini A, Leach MO, Bifone A (2000) Hyperpolarized129Xe NMR as a probe for blood oxygenation. Magn Reson Med 43:491–496CrossRefPubMed

23.

Plummer JW, Willmering MM, Cleveland ZI, Towe C, Woods JC, Walkup LL (2023) Childhood to adulthood: accounting for age dependence in healthy-reference distributions in 129Xe gas-exchange MRI. Magn Reson Med 89:1117–1133. https://doi.org/10.1002/mrm.29501CrossRefPubMed

24.

Bechtel A, Lu J, Mummy D et al (2023) Establishing a hemoglobin adjustment for ¹²⁹Xe gas exchange MRI and MRS. Magn Reson Med 90:1555–1568. https://doi.org/10.1002/mrm.29712CrossRefPubMedPubMedCentral

25.

Ladefoged J, Andersen AM (1967) Solubility of Xenon-133 at 37 °C in water, saline, olive oil, liquid paraffin, solutions of albumin, and blood. Phys Med Biol 12:307. https://doi.org/10.1088/0031-9155/12/3/307CrossRef

26.

Garrison WJ, Qing K, He M et al (2023) Lung volume dependence and repeatability of hyperpolarized ¹²⁹Xe MRI gas uptake metrics in healthy volunteers and participants with COPD. Radiol Cardiothorac Imaging 5:e220096. https://doi.org/10.1148/ryct.220096CrossRefPubMedPubMedCentral

27.

Robert HB, Robert AW, Kirk G, Drummond MB, Mitzner W (2015) Lung density changes with growth and inflation. Chest 148:995–1002. https://doi.org/10.1378/chest.15-0264CrossRefPubMed

28.

Niedbalski PJ, Hall CS, Castro M et al (2021) Protocols for multi‐site trials using hyperpolarized ¹²⁹Xe MRI for imaging of ventilation, alveolar‐airspace size, and gas exchange: a position paper from the ¹²⁹Xe MRI clinical trials consortium. Magn Reson Med 86:2966–2986. https://doi.org/10.1002/mrm.28985CrossRefPubMed

Titel: Loss of pulmonary capillaries in idiopathic pulmonary arterial hypertension with low diffusion capacity is accompanied by early diffuse emphysema detected by 129Xe MRI
verfasst von: Agilo Luitger Kern
Da-Hee Park
Jan Fuge
Jens M. Hohlfeld
Frank Wacker
Marius M. Hoeper
Karen M. Olsson
Jens Vogel-Claussen
Publikationsdatum: 08.12.2024
Verlag: Springer Berlin Heidelberg
Erschienen in: European Radiology
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-024-11209-1

Neu im Fachgebiet Radiologie

KI-gestütztes Mammografiescreening überzeugt im Praxistest

16.01.2025
Künstliche Intelligenz im Gesundheitswesen
Nachrichten

Mit dem Einsatz künstlicher Intelligenz lässt sich die Detektionsrate im Mammografiescreening offenbar deutlich steigern. Mehr unnötige Zusatzuntersuchungen sind laut der Studie aus Deutschland nicht zu befürchten.

Stumme Schlaganfälle − ein häufiger Nebenbefund im Kopf-CT?

12.01.2025
Computertomografie
Nachrichten

In 4% der in der Notfallambulanz initiierten zerebralen Bildgebung sind „alte“ Schlaganfälle zu erkennen. Gar nicht so selten handelt es sich laut einer aktuellen Studie dabei um unbemerkte Insulte. Bietet sich hier womöglich die Chance auf ein effektives opportunistisches Screening?

Die elektronische Patientenakte kommt: Das sollten Sie jetzt wissen

12.01.2025
Elektronische Patientenakte
Nachrichten

Am 15. Januar geht die „ePA für alle“ zunächst in den Modellregionen an den Start. Doch schon bald soll sie in allen Praxen zum Einsatz kommen. Was ist jetzt zu tun? Was müssen Sie wissen? Wir geben in einem FAQ Antworten auf 21 Fragen.

Stören weiße Wände und viel Licht die Bildqualitätskontrolle?

09.01.2025
Mammografie
Nachrichten

Wenn es darum geht, die technische Qualität eines Mammogramms zu beurteilen, könnten graue Wandfarbe und reduzierte Beleuchtung im Bildgebungsraum von Vorteil sein. Darauf deuten zumindest Ergebnisse einer kleinen Studie hin.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Objectives

Materials and methods

Results

Conclusion

Key Points

Supplementary information

Introduction

Materials and methods

Participants

129Xe application

Imaging

Statistical analysis

Results

Participants

Imaging

Correlations

Discussion

Limitations

Conclusion

Supplementary information

Acknowledgements

Compliance with ethical standards

Guarantor

Conflict of interest

Statistics and biometry

Informed consent

Ethical approval

Study subjects or cohorts overlap

Methodology

Unsere Produktempfehlungen

e.Med Interdisziplinär

e.Med Radiologie

Supplementary information

KI-gestütztes Mammografiescreening überzeugt im Praxistest

Stumme Schlaganfälle − ein häufiger Nebenbefund im Kopf-CT?

Die elektronische Patientenakte kommt: Das sollten Sie jetzt wissen

Stören weiße Wände und viel Licht die Bildqualitätskontrolle?

Update Radiologie

¹²⁹Xe application